Omega Fund Management, LLC
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$125.2M2026 Q3
Positions10
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
What Changed This Quarter?
Top Holdings
NUVB
Nuvation Bio
32.0%
BCAX
Bicara Therapeutics
26.2%
BBNX
Beta Bionics
14.6%
BBOT
BridgeBio Oncology Therapeutics
10.8%
KMTS
Kestra Medical Technologies
8.2%
IMUX
Immunic
3.2%
SANA
Sana Biotechnology
2.0%
IMA
ImageneBio
1.7%
Reduced / Exited
4 reduced · 1 sold out
KMTS
Kestra Med Technologies
8.2%
-64.5%
BBNX
Beta Bionics
14.6%
-26.9%
NUVB
Nuvation Bio
32.0%
-11.5%
BCAX
Bicara Therapeutics
26.2%
-3.4%
ALMSEXIT
Alumis
3.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.